Classical psychedelics are not addictive, show promise for a broad spectrum of medical uses, and have been repeatedly proven safe in clinical settings, despite UN assertions and occasional media disinformation about their dangers. The article briefly describes the history of psychedelic research in the Czech Republic since the early 19th century, summarizes the role of the UN Drug Conventions, and discusses Czech and international legislation. It also suggests a procedure for preparing and implementing controlled psychedelic therapy within the Czech medical and legal system.
Psychedelic-assisted psychotherapy (PAP) shows cautious clinical potential for treating substance use disorders, but the evidence remains heterogeneous and largely from observational, open-label, or historical studies rather than strong randomized controlled trials. In the Czech Republic, recent developments include ketamine-assisted psychotherapy initiatives, inclusion of PAP in national addictology guidance, publication of national psychiatry guidelines for psilocybin-assisted psychotherapy, and a 2025 legislative reform introducing psilocybin for medical use from January 2026. Broader integration will require clearer indications, accredited training, longitudinal outcome monitoring, and transparent communication of benefits and risks.